|Home | About | Journals | Submit | Contact Us | Français|
Poor adherence to treatment is difficult to diagnose accurately. Hydroxychloroquine (HCQ) has a long elimination half‐life and its concentration in whole blood can be measured easily.
To evaluate the utility of a very low blood HCQ concentration as a marker of poor compliance in patients with systemic lupus erythematosus (SLE).
HCQ concentrations were determined on a blinded basis in 203 unselected patients with SLE. At the end of the study, the patients were informed of the results and retrospectively interviewed about their adherence to treatment.
14 (7%) patients said that they had stopped taking HCQ (n=8) or had taken it no more than once or twice a week (n=6). Their mean (SD) HCQ concentration was 26 (46) ng/ml. range (0–129 ng/ml) By contrast, the other patients had a mean HCQ concentration of 1079 ng/ml range (205–2629 ng/ml). The principal barriers to adherence were related to HCQ treatment characteristics. Adherence subsequently improved in 10 of the 12 patients whose blood HCQ concentrations were remeasured.
Very low whole‐blood HCQ concentrations are an objective marker of prolonged poor compliance in patients with SLE. Regular drug assays might help doctors in detect non‐compliance and serve as a basis for counselling and supporting these patients.
Poor adherence to therapeutic regimens is a common and expensive problem in patients with chronic diseases and is difficult to diagnose.1 Rates of non‐compliance in patients with systemic lupus erythematosus (SLE) range from 10% to 50%,2,3,4,5,6,7 depending on the methods used to evaluate it; methods that are debatable.1 A simple, objective and reliable marker of non‐compliance with medications in patients with SLE is needed.
Hydroxychloroquine (HCQ) is widely used in patients with SLE, and HCQ levels in blood can be quantified by high‐performance liquid chromatography.8 We found in a recent study that several patients had undetectable blood HCQ concentrations.8 As HCQ has a long terminal elimination half‐life, this finding implied that these patients had not taken HCQ for a long time. This result prompted us to evaluate the possibility of very low blood HCQ concentrations as a marker of poor adherence to treatment.
This study cohort involved 203 unselected outpatients and inpatients receiving long‐term follow‐up from June 2000 to November 2004 at the Pitié‐Salpêtrière Hospital, Paris, France (143 patients were included in a previous study).8 All patients met the American College of Rheumatology criteria for SLE, were treated with HCQ prescribed at a stable oral dose of 400 or 200 mg/day for at least 6 months, could easily contact their hospital physician if they developed symptoms of flare, had regular follow‐up appointments at least every 6 months, were >15 years, not pregnant and had no serious ophthalmic disorders.
The study design has been described previously.8 All the patients were unaware that HCQ levels could be assessed until they attended our clinic, when they received information about the study, provided informed consent and had a first blood sample taken (day 0). No patient refused to participate in the study. SLE flares, defined by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of >6 , were recorded on day 0 and throughout 6 months of follow‐up for patients without flares on day 0, as detailed previously.8
Blood collected at day 0 was analysed by high‐performance liquid chromatography8 once the patient had completed the study.
Doctors provided their patients with the assay results and then interviewed them non‐judgementally, which facilitated an open discussion.1 Patients were classified as non‐compliant if they admitted that they had stopped HCQ or taken it only rarely in the weeks before day 0. Non‐compliant patients were asked about the reasons for their non‐compliance and about their compliance with other treatments for SLE during the same period.
Comparisons between non‐compliant and other patients used the χ2 test or Fisher's exact test for categorical variables and the Mann–Whitney U test for data with a non‐normal distribution.
The study included 203 patients. Table 11 reports their demographic and clinical characteristics and laboratory findings. Mean (SD) blood HCQ concentration on day 0 was 1007 (529) ng/ml. We found large interindividual variations for all patients and for comparisons limited to patients taking either 200 or 400 mg daily (fig 11,, table 11).
A total of 14 (7%) patients with SLE said that they had stopped taking HCQ (n=8) or they took it no more than once or twice a week (n=6). Mean duration of non‐compliance was 17 months (range 1–56 months). Their mean (SD) HCQ concentration was 26 (46) ng/ml. Blood HCQ concentrations were undetectable in eight patients and ranged from 10 to 129 ng/ml in the other six patients.
All other patients reported either good adherence or only few omissions. Their mean (SD) HCQ concentration was 1079 ng/ml (range 205–2629 ng/ml).
Regarding demographic, clinical and laboratory variables, the only indicator of non‐compliance was the SLEDAI score, which was higher on day 0, given the higher risk of ongoing SLE flare in non‐adherent patients.
During the year before day 0, 12 of the 14 non‐compliant patients had come regularly to their routine appointments, without missing any. None reported difficulties with adherence to treatment. All had regularly undergone their routine yearly electroretinogram from onset of HCQ treatment. Before the HCQ results were available, doctors suspected non‐compliance in only 5 (36%) of these 14, owing to psychological or psychiatric troubles (n=4) or absence of Cushing's syndrome (n=1). However, these five patients had always denied poor adherence.
Of these 14 patients, 10 also took corticosteroids, associated with immunosuppressive agents in 4. Four of them admitted poor compliance with these treatments.
Patients attributed non‐compliance to HCQ characteristics in 9 (64%) cases: four reported concern about potential side effects, three perceived HCQ to be ineffective compared with other treatments and two had experienced adverse side effects (vomiting and dizziness). Patient characteristics accounted for the remaining five cases of non‐adherence: three admitted that they did not accept their disease and thought that they did not need treatment, one was “bored” with taking treatment, and another reported “forgetting” very frequently.
During the discussion with non‐compliant patients, doctors again informed them about the benefit/risk ratio for HCQ treatment in SLE. In the months that followed, two patients decided to be treated in another hospital. The remaining 12 underwent a second unscheduled blood sample and HCQ assay, 13 (7) months later (fig 22).). Mean (SD) blood HCQ increased significantly, from 30 (49) ng/ml to 636 (354) ng/ml (range 0–1157 ng/ml; p=0.001), but remained significantly lower that the mean blood HCQ concentration of the entire cohort (p=0.01).
Two patients reported continued non‐compliance, one (HCQ concentration 0 ng/ml) because of persistent side effects and the other (56 ng/ml) because of persistent concern about ophthalmological risks.
For comparison, we subsequently assayed HCQ concentration in 130 of the other 189 patients: their mean concentration did not differ significantly from that on day 0 (fig 22).
At day 0, 7 of the 14 (50%) non‐compliant patients had SLE flares, compared with 28 of the other 189 (15%) patients (p=0.004).
During the 6‐month follow‐up period, 3 of the 7 (43%) non‐compliant patients with inactive SLE at day 0 developed flares, a significantly higher flare rate compared with other patients with inactive SLE at day 0 (13/161; 8%; p=0.02). Overall, 10 of the 14 (71%) non‐compliant patients had active SLE (SLEDAI 6) on either day 0 or during the 6 months afterwards.
Non‐compliance with treatment is a major problem in the management of chronic diseases, but there is no satisfactory method of measuring compliance with medication.1,10,11 Patient self‐reports, clinician's assessments or suspicions, keeping appointments, pill count, the refilling approach and electronic monitoring devices that record the opening of the pill container are either disputable or not routinely applicable.1,11,12,13 Objective methods, such as unscheduled blood or urine samples, are often limited by the unavailability or cost of sensitive assays, the frequent need for repeated sampling (due to the short half‐life) and their inability to identify poor long‐term compliance in patients whose compliance improves shortly before the doctors' appointment (“white‐coat compliance”).1,14 Because of its long terminal elimination half‐life (>40 days), these limitations do not apply to blood HCQ assays.
Poor adherence was confirmed by 14 (7%) patients in the interviews, during which they were confronted with their blood HCQ levels. Their HCQ concentrations were <130 ng/ml, whereas all other patients had levels >205 ng/ml. This percentage is consistent with the 5–10% of patients who completely stopped or frequently interrupted tablet ingestion in studies using electronic monitoring.11,12
We were unable to identify any risk factors for, or indicators of, non‐adherence except for ongoing SLE flares. Even if this may be attributable to the small number of patients, these results are consistent with previous studies that report conflicting results about these risk factors.1,2,3,4,5,6,15 As some have emphasised, “adherence is so difficult to diagnose because it is a task‐specific behavior rather than a personality trait”.13
The doctors treating 9 (64%) of these 14 patients did not suspect non‐compliance. This is not surprising as clinical judgment has been found wanting in almost every study in which it has been examined.1 The remaining five patients denied non‐compliance until faced with the blood test result. This finding suggests that interviews without blood HCQ results are likely to be insufficient for diagnosing non‐compliance.
The main barriers to patient compliance were due to HCQ treatment characteristics. After provision of new explanations, HCQ concentrations rose significantly in most patients, confirming that doctors' awareness of non‐compliance is an essential prerequisite for improving adherence.
The clinical consequences of non‐compliance were substantial: very low blood HCQ concentrations at baseline were strongly associated with ongoing disease activity and, in patients with inactive SLE at day 0, with the risk of further SLE flares during the following 6 months. Even after exclusion of these 14 non‐compliant patients, low blood HCQ concentrations remained significantly associated with SLE flares (data not shown), confirming our previous results.8
Two specific limitations of our study should be pointed out. First, two separate independent patterns of non‐adherence have been described11—(a) relatively infrequently missed medication, and (b) complete stopping or frequently interrupted and erratic tablet intake—and low HCQ concentrations can identify only the latter. Patients who missed some medication had blood HCQ concentrations >205 ng/ml and were thus indistinguishable from those who reported good adherence. Another limitation of our study was the lack of objective assessment of non‐compliance with other treatments.
In conclusion, these findings strongly suggest that unscheduled, regular assays of HCQ levels in whole blood are a reliable, simple and objective method for identifying non‐adherent patients with SLE: undetectable or unexpectedly low HCQ concentrations should prompt a non‐judgemental discussion with the patient. Determination of blood HCQ concentration, available within few days in our centre, may be helpful for doctors confronted with a flare as it may prevent incorrect interpretation of poor compliance as a lack of response, and lead to unnecessary or even dangerous regimen escalation. HCQ assays may also help to prevent SLE flares by detecting non‐compliant patients with currently inactive SLE who are at high risk of further flares and by making it possible to conduct specific interventions to improve their compliance.
HCQ - Hydroxychloroquine
SLE - systemic lupus erythematosus
SLEDAI - Systemic Lupus Erythematosus Disease Activity Index
Competing interests: None.